

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/211857 A1

(51) International Patent Classification:

A61K 38/17 (2006.01) *A61P 35/00* (2006.01)
A61K 38/20 (2006.01) *C07K 14/55* (2006.01)
A61K 39/395 (2006.01) *C07K 14/715* (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(21) International Application Number:

PCT/US2021/027503

(22) International Filing Date:

15 April 2021 (15.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/010,185 15 April 2020 (15.04.2020) US
63/165,391 24 March 2021 (24.03.2021) US

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **ALKERMES PHARMA IRELAND LIMITED** [IE/IE]; One Burlington Road, Connaught House, Dublin 4 (IE).

(72) Inventor; and

(71) Applicant (for US only): **LOPES, Jared** [US/US]; 9 Hillside Way, Wilmington, MA 01887 (US).

(72) Inventors: **LOSEY, Heather, C.**; 12 Taft Avenue, Lexington, MA 02421 (US). **WINQUIST, Raymond, J.**; 196 Carolyn Circle, Marshfield, MA 02050 (US).

(74) Agent: **SPELLBERG, Michael** et al.; Lathrop GPM LLP, 28 State Street, 7th Floor, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS

(57) Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).

WO 2021/211857 A1